Answers are grounded in this paper and cite their sources.
During the first 12 weeks of treatment, iGlarLixi was generally associated with less nausea and vomiting than single-agent GLP-1 RAs. Enhanced gastrointestinal tolerability with fixed-ratio combinations may favour treatment persistence.
No takes yet. Share an insight, caveat, or question.
Rayner et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: